Karo Bio AB - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Karo Bio AB - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Karo Bio AB - Product Pipeline Review - 2014', provides an overview of the Karo Bio AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Karo Bio AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Karo Bio AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Karo Bio AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Karo Bio AB's pipeline products

Reasons to buy

- Evaluate Karo Bio AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Karo Bio AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Karo Bio AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Karo Bio AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Karo Bio AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Karo Bio AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Karo Bio AB Snapshot 5
Karo Bio AB Overview 5
Key Information 5
Key Facts 5
Karo Bio AB - Research and Development Overview 6
Key Therapeutic Areas 6
Karo Bio AB - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Karo Bio AB - Pipeline Products Glance 13
Karo Bio AB - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Karo Bio AB - Drug Profiles 15
Estrogen Receptor Program 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Glucocorticoid Receptor Agonist 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
KB-9520 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Drug Targeting Nuclear Receptor for Fibrotic Diseases 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Drug Targeting Nur-77 Receptor for Autoimmune Disorders 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Drug Targeting NURR-1 Receptor 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ROR-gamma Program 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Karo Bio AB - Pipeline Analysis 22
Karo Bio AB - Pipeline Products by Target 22
Karo Bio AB - Pipeline Products by Route of Administration 23
Karo Bio AB - Pipeline Products by Molecule Type 24
Karo Bio AB - Pipeline Products by Mechanism of Action 25
Karo Bio AB - Recent Pipeline Updates 26
Karo Bio AB - Dormant Projects 27
Karo Bio AB - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
eprotirome 28
KB-002611 28
KB-5359 28
Karo Bio AB - Company Statement 29
Karo Bio AB - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Karo Bio AB, Key Information 5
Karo Bio AB, Key Facts 5
Karo Bio AB - Pipeline by Indication, 2014 8
Karo Bio AB - Pipeline by Stage of Development, 2014 9
Karo Bio AB - Monotherapy Products in Pipeline, 2014 10
Karo Bio AB - Out-Licensed Products in Pipeline, 2014 11
Karo Bio AB - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Karo Bio AB - Preclinical, 2014 13
Karo Bio AB - Discovery, 2014 14
Karo Bio AB - Pipeline by Target, 2014 22
Karo Bio AB - Pipeline by Route of Administration, 2014 23
Karo Bio AB - Pipeline by Molecule Type, 2014 24
Karo Bio AB - Pipeline Products by Mechanism of Action, 2014 25
Karo Bio AB - Recent Pipeline Updates, 2014 26
Karo Bio AB - Dormant Developmental Projects,2014 27
Karo Bio AB - Discontinued Pipeline Products, 2014 28
Karo Bio AB, Subsidiaries 31